

WO 2013/130351 A1 * WO, 2013 / 130351 A1 *

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 September 2013 (06.09.2013) WIPO | PCT

* WO, 2013 / 130351, A1 *

(10) International Publication Number

WO 2013/130351 A1

(51) International Patent Classification:

C07K 14/315(2006.01)

(21) International Application Number:

PCT/US2013/027340

(22) International Filing Date:

22 February 2013 (22.02.2013)

(25) Filing Language:

English

(26) Publication Language

English

(30) Priority Data:

61/603,693 27 February 2012 (27.02.2012) US
61/603,661 27 February 2012 (27.02.2012) US

(71) Applicants: ORAGENICS, INC. [US/US]; 13700 Progress Boulevard, Alachua, FL 32615 (US). THE TEXAS A&M UNIVERSITY SYSTEM [US/US]; Office of Technology Commercialization, 800 Raymond Stotzer Parkway, Suite 2020, College Station, Texas 77845 (US).

(72) Inventors: HILLMAN, Jeffrey D. ; 6424 SW 26th Place, Gainesville, FL 32608 (US). SMITH, James Leif, 606 Coachlight Court, College Station, TX 77845 (US). WILSON-STANFORD, Shawanda R; 1109 Southwest Parkway, Apartment 1811, College Station, TX 77840 (US).

• (74) Agent: HILLMAN, Lisa, M.W. ; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published

— with international search report (Art. 21(3))

(54) Title: REPLACEMENT THERAPY FOR DENTAL CARIES




Figure 1A
Wild-type (native) MU1140

(57) Abstract: The invention provides recombinant *Streptococcus mutans* strains that can be used to improve oral health. An embodiment of the invention provides a method of reducing the incidence or severity of dental caries in a dental caries-susceptible host comprising administering orally to the host an isolated recombinant *S. mutans* strain of the invention in an amount effective for the placement of dental caries-causing *S. mutans* host strains in the oral cavity of the host. The isolated recombinant *S. mutans* strain can be contained in a mouthwash, toothpaste, chewing gum, floss, chewable tablet, food, or beverage.

TITLE: Replacement Therapy for Dental Caries**PRIORITY**

This application claims the benefit of U.S. provisional application 61/603,661, filed February 27, 2012, and U.S. provisional application 61/603,693, filed February 5, 2012, both of which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

Dental caries are one of the most prevalent chronic infectious diseases in the world. Over half of U.S. children age 5 – 9 have at least one cavity or filling; by age 17, nearly 80% of our young people have had a cavity. U.S. Department of Health 10 and Human Services. *Oral Health in America: A Report of the Surgeon General—Executive Summary*. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, 2000.

Annual expenditures on the treatment of dental caries in the U.S. are 15 estimated to be \$40 billion a year according to the Dental, Oral and Craniofacial Data Resource Center. Tooth decay is characterized by the demineralization of enamel and dentin, eventually resulting in the destruction of the teeth. Dietary sugar is often misperceived as the cause of tooth decay; however, the immediate cause of tooth decay is lactic acid produced by microorganisms that metabolize sugar on the 20 surface of the teeth. Studies suggest that of the approximately 700 oral microorganisms, *Streptococcus mutans*, a bacterium found in virtually all humans, is the principal causative agent in the development of tooth decay. Residing within dental plaque on the surface of teeth, *S. mutans* derives energy from carbohydrate metabolism as it converts dietary sugar to lactic acid which, in turn, promotes 25 demineralization in enamel and dentin, eventually resulting in a cavity. The rate at which mineral is lost depends on several factors, including the number of *S. mutans* cells that are present and the frequency and amount of sugar that is consumed.

Therapeutic regimens that take advantage of bacterial interference to replace 30 a pathogenic bacterial strain such as *S. mutans* with a non-pathogenic, effector strain are known as replacement therapies. Successful replacement therapy requires an effector strain that: 1) is non-pathogenic, 2) alters the microenvironment to prevent colonization or outgrowth of a pathogenic organism, and 3) persistently colonizes the host at risk to prevent reinfection by the target pathogenic organism,

and aggressively displaces the pathogenic organism from the tissues at risk in the case where the pathogen is part of the host's indigenous flora.

Application of the principles of replacement therapy requires the isolation of a non-cariogenic effector strain of *S. mutans*, e.g., an *S. mutans* strain deficient in lactic acid synthesis that can outcompete native *S. mutans* in the oral cavity of the host. There is a need in the art for stable, lactic acid-deficient, non-cariogenic strains of *S. mutans* that can persistently colonize and aggressively outcompete native *S. mutans* in the oral cavities of the hosts, and that are suitable for use in a replacement therapy in the prevention and/or treatment of dental caries.

The ability of an effector strain to preemptively colonize the human oral cavity and aggressively displace indigenous wild-type strains was initially thought to be a complex phenomenon dependent on a large number of phenotypic properties. However, it was discovered that a single phenotypic property could provide the necessary selective advantage. A naturally occurring strain of *S. mutans* was isolated from a human subject that produces a lantibiotic called MU1140, which is capable of killing virtually all other strains of mutans streptococci against which it was tested. See e.g., Hillman *et al.*, Infect. Immun. 44:141 (1984). Mutants were isolated that produced no detectable MU1140 or that produced approximately three-fold elevated amounts. The mutants were used in a rat model to correlate lantibiotic production to colonization potential. It was found that the ability of these strains to preemptively colonize the host and aggressively displace indigenous strains of *S. mutans* increased significantly as the amount of MU1140 produced increased.

The same relationship between MU1140 production and colonization potential was observed in human subjects, where repeated exposures to the wild-type parent strain were required to achieve persistent colonization (Hillman *et al.* J. Dent. Res. 66:1092 (1985)), whereas a single exposure to the strain producing three-fold elevated amounts of MU1140 was sufficient (Hillman *et al.* J. Dent. Res. 66:1092 (1987)). The latter strain required over a year to completely replace indigenous strains of *S. mutans* in the mouths of the human subjects. During this period, it is presumed that their susceptibility to dental caries persisted until the levels of indigenous *S. mutans* decreased below a threshold level.

In order to further increase the colonization potential of an effector strain for replacement therapy of dental caries, it is desirable to obtain one or more strains of

S. mutans that produce elevated amounts of MU1140 or produce variants of this molecule with increased specific activity. Such strains would reduce the period required for the effector strain to eliminate indigenous, lactic acid-producing strains and thereby achieve full effectiveness. Such strains are also more likely to 5 overcome any inherent resistance to colonization, which, while not currently known, may exist in certain individuals in the population being treated. See, e.g., Hillman, *Antonie van Leeuwenhoek* 82: 361–366, 2002.


SUMMARY OF THE INVENTION

In one embodiment the invention provides an isolated recombinant 10 *Streptococcus mutans* strain comprising:

(a) a mutation in a polynucleotide involved in lactic acid synthesis such that expression of lactic acid is diminished by about 80% or more as compared to a wild-type *S. mutans* strain;

(b) a recombinant alcohol dehydrogenase polynucleotide;

15 (c) a recombinant polynucleotide encoding a lantibiotic comprising Formula I:



(SEQ ID NO:1), wherein the following mutations are present: a Phe1Ile mutation or a Phe1Gly mutation; a Trp4Ala mutation; a Dha5Ala mutation; an Arg13Asp mutation; 20 or combinations of two or more of these mutations. The strain can further comprise a Trp4insAla mutation or a ΔTrp4 mutation. The following amino acid substitutions can also be present: Abu8Ala, or Dhb14Ala, or both Abu8Ala and Dhb14Ala. The strain can further comprise a mutation in a polynucleotide involved in ComE, ComC, or both ComE and ComC synthesis such that expression of ComE, ComC, or both 25 ComE and ComC is diminished by about 80% or more as compared to a wild-type *S. mutans* strain. The strain can further comprising a mutation in a polynucleotide involved in D-amino acid synthesis such that expression of the D-amino acid is diminished by about 80% or more as compared to a wild-type *Streptococcus mutans*

strain. The polynucleotide involved in D-amino acid synthesis can be *dal* or a promoter for *dal*. The recombinant alcohol dehydrogenase polynucleotide can be a *Zymomonas mobilis* alcohol dehydrogenase polynucleotide or a *Streptococcus mutans* alcohol dehydrogenase polynucleotide.

5 Another embodiment of the invention provides a method of reducing the incidence or severity of dental caries in a dental caries-susceptible host comprising administering orally to the host an isolated recombinant *S. mutans* strain of the invention in an amount effective for replacement of dental caries-causing *S. mutans* host strains in the oral cavity of the host. The isolated recombinant *S. mutans* strain
10 can be contained in a mouthwash, toothpaste, chewing gum, floss, chewable tablet, food, or beverage.

15 Still another embodiment of the invention provides a pharmaceutical composition for reducing the incidence or severity of dental caries comprising an isolated recombinant *S. mutans* strain of the invention and a pharmaceutically acceptable carrier.

Therefore, the invention provides strains of *S. mutans* that are stable, lactic acid-deficient, and non-cariogenic that can aggressively outcompete native *S. mutans* due to, *inter alia*, the expression of a variant MU1140 lantibiotic that has improved biological activity as compared to a wild-type MU1140 lantibiotic.

20 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1A shows the wild-type MU1140 structure (SEQ ID NO:1). Figure 1B shows mutation sites of MU1140 (SEQ ID NO:2).

25 Figure 2 shows the sequence of chromosomal DNA highlighting mutations of variant MU1140 *lanA* polynucleotide sequences with the wild type MU1140 *lanA* polynucleotide sequence.

Figure 3 shows the primers used for mutagenesis of *lanA*, the MU1140 structural gene.

Figure 4A-B shows the results of the zone of inhibition plate assays.

30 Figure 5 shows the means and standard deviations for the bioactivity of strains producing variants of MU1140 compared to wild-type MU1140.

Figure 6 shows the biological activity of strains producing variants of MU1140 (Phe1Ile and Phe1Gly) compared to wild-type MU1140.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

Streptococcus mutans can be recombinantly manipulated to produce no lactic acid or substantially reduced amounts of lactic acid. Hillman *et al.* *J. Appl. Microbiol.* 5 102:1209 (2007). Viable, lactic acid-deficient *S. mutans* strains can be generated by transforming the strains with nucleic acid encoding a recombinant alcohol dehydrogenase (ADH) such that a recombinant alcohol dehydrogenase is expressed, and introducing a mutation in the lactic acid synthesis pathway to render the recombinant ADH-producing strain lactic acid deficient. The recombinant ADH 10 prevents accumulation of metabolites in the bacterium, thus circumventing any lethality of the lactic acid deficiency. Furthermore, *S. mutans* strains can be recombinantly engineered to express a variant MU1140 lantibiotic that has greater biological activity than wild-type MU1140 lantibiotics. These strains can outcompete and replace dental caries-causing wild-type, native *S. mutans* strains in the oral 15 cavity of hosts.

Parent *Streptococcus mutans* Strains

Any *S. mutans* strains can be used to construct the recombinant *S. mutans* strains of the invention. Recombinant *S. mutans* strains of the invention have a selective advantage over wild-type *S. mutans* strains that normally colonize the oral 20 cavity. The selective advantage can be conferred by any of a variety of characteristics (e.g., production of an antibacterial compound, reduced or advantageous relative metabolic needs, greater relative growth rate, production of scavengers for metabolites) that promote oral cavity colonization by the strain and replacement of the resident strain colonizing the oral cavity. In one embodiment of 25 the invention, colonization by the recombinant *S. mutans* strains of the invention will not substantially disrupt colonization by other, non-*S. mutans* strains (e.g., normal bacterial flora not associated with cariogenesis). For example, infection with a recombinant strain of *S. mutans* that produces a variant MU1140 lantibiotic with enhanced lantibiotic activity can result in replacement of the resident, cariogenic *S. 30 mutans* strains without effect upon other resident microbial species of the oral cavity.

Recombinant *Streptococcus mutans* Strains

A recombinant *S. mutans* strain is a non-naturally occurring strain of *S. mutans* that has been generated using any of a variety of recombinant nucleic acid

techniques (i.e., techniques involving the manipulation of DNA or RNA). In general, a recombinant *S. mutans* strain of the invention has a deficiency in lactic acid production; expresses a recombinant alcohol dehydrogenase (ADH) polypeptide; and expresses recombinant polypeptides sufficient to produce a variant MU1140 5 lantibiotic that has greater biological activity than wild-type MU1140. Recombinant strains of *S. mutans* can optionally be deficient in ComE, ComC, or both ComE and ComC expression and/or can optionally be auxotrophic for an organic substance not normally present in the oral cavity or diet of a particular host (e.g., a D-amino acid).

Variant MU1140

10 MU1140 has an overall horseshoe-like shape kinked at the "hinge region" between rings B and C. Smith *et al.* (2003) *Biochem.* 42:10372-10384. This shape is the result of a turn-like motif in the hinge region that folds the amino-terminal AB rings (the lipid II binding domain) towards the carboxy-terminal overlapped rings CD. The flexibility of the hinge region is believed to be important in promoting lateral 15 assembly of MU1140, enabling it to abduct and sequester lipid II. The Ψ angle of Trp4 and Φ angle of Dha5 in ring A help contribute to its flexibility. Also it was determined that the Ψ bond of sAla7 (a residue that is not confined by the thioether ring) rotates 360° allowing ring A to spin freely with respect to ring B. This flexibility is thought to be important in orienting rings A and B during lipid II binding. The hinge 20 region also contains a potentially enzymatically susceptible arginine at residue 13. Mutations in the structural gene (*lanA*) for MU1140 were generated to determine the effect of the following amino acid alterations: Phe1Ile, Phe1Gly, Trp4Ala, Trp4insAla, Δ Trp4, Dha5Ala, Ala_s7insAla, and Arg13Asp. Figure 1B.

It was found that the variants of MU1140 possessing a deletion of Trp4 or 25 insertion of Ala after Trp4 showed bioactivity activity approximately equivalent to the wild-type in a deferred antagonism assay using *Micrococcus luteus* strain ATCC 272 as the target strain. Wilson-Sanford *et al.*, (2009) *Appl. Environ. Microbiol.* 75:1381. In this assay, activity is determined by calculating the area of the zone of inhibition. These results indicate that shortening or lengthening ring A had no beneficial or 30 deleterious effect on MU1140 activity, indicating an unexpected permissiveness in the structure of ring A. As shown in Figure 5, the Trp4Ala substitution resulted in a statistically significant ($p<.05$) increase in bioactivity when compared to the wild-type. Since both amino acids are uncharged and hydrophobic, it can be speculated that

the difference in bioactivity was due to the size difference between the two amino acids. Replacement of Dha5 with Ala also resulted in a statistically significant ($p<.05$) increase in bioactivity. Insertion of alanine after s Ala at position 7 resulted in a significant ($p<.05$) reduction of bioactivity. While not wishing to be bound to any particular theory, since it has been determined that s Ala7 freely rotates 360° allowing ring A to spin freely with respect to ring B, it could be concluded that the $Ala_87insAla$ mutation changed the orientation of the rings during lipid II binding, possibly affecting the affinity of the molecule for its substrate, lipid II. The Arg13Asp substitution showed a very significant ($p<.05$) increase in bioactivity when compared to the wild-type. While not wishing to be bound to any particular theory, the observed effect may be the result of increased solubility. As shown in Figure 6, both the Phe1Ile and the Phe1Gly substitutions resulted in statistically significant ($p<.05$) increases in bioactivity when compared to the wild-type. It is noteworthy that substitution of Arg (AGA/AGG/CGT/CGC/CGA/CGG) with Asp (GAT/GAC) or the substitution of Ala (GCT/GCT/GCA/GCG) for Trp (TGG) or the substitution of Ala (GCT/GCT/GCA/GCG) for Ser (AGT/AGC) or the substitution of Ile (ATT/ATG) or Gly (GGT/GGC/CCA/GGG) for Phe (TTT/TTC) are all very unlikely to occur in nature since they involve multiple point mutations, which may include one or more transversions in the affected codon. While not wishing to be bound to any particular theory, the basis for the increase may be due to increased binding affinity to the lipid II target or to improved efficiency in cleavage of the leader sequence. An effector strain producing a variant MU1140 possessing one or more of these site-directed changes (Phe1Ile, Phe1Gly, Trp4Ala, Dha5Ala, and Arg13Asp) has the potential to be superior to an effector strain producing wild type MU1140 by improving its ability to colonize the oral cavity and aggressively displace disease-causing, indigenous strains of *S. mutans*.

Variants of the lantibiotic MU1140 of the invention are polypeptides comprising post-translational modifications. Post-translational modifications are chemical modifications of a polypeptide after it has been translated. A polypeptide is a polymer of two or more amino acids covalently linked by amide bonds. A purified polypeptide is a polypeptide preparation that is substantially free of cellular material, other types of polypeptides, chemical precursors, chemicals used in synthesis of the polypeptide, or combinations thereof. A polypeptide preparation that is substantially

free of cellular material, culture medium, chemical precursors, chemicals used in synthesis of the polypeptide, etc., has less than about 30%, 20%, 10%, 5%, 1% or more of other polypeptides, culture medium, chemical precursors, and/or other chemicals used in synthesis. Therefore, a purified polypeptide is about 70%, 80%, 5 90%, 95%, 99% or more pure. A purified polypeptide does not include unpurified or semi-purified cell extracts or mixtures of polypeptides that are less than 70% pure.

Wild-type MU1140 is shown in Figure 1A. MU1140 has four rings labeled A, B, C, and D. Two of these rings are formed by lanthionine (Ala-S-Ala) residues, including one in Ring A (Ala₃-S-Ala₇) and one in Ring C (Ala₁₆-S-Ala₂₁); there is a 10 methyl-lanthionine residue (Abu-S-Ala) that forms Ring B comprised of the α -aminobutyrate residue in position 8 and the Ala in position 11 (Abu₈-S-Ala₁₁); and the fourth ring, D, is comprised of the Ala in position 19 linked to an aminovinyl group by a thioether linkage (Ala₁₉-S—CH=CH—NH—).

One embodiment of the invention provides one or more of the following 15 variants of the lantibiotic mutacin, MU1140, shown in Figure 1B (SEQ ID NO:2). That is, the invention includes variants of the wild-type lantibiotic MU1140 (SEQ ID NO:1) with one or more of the following mutations:

1. Phe1Ile or Phe1Gly; that is the phenylalanine at position 1 is changed to isoleucine or glycine.
- 20 2. Trp4Ala; that is, the tryptophan at position 4 is changed to alanine.
3. Dha5Ala; that is, the 2,3-didehydroalanine at position 5 is changed to alanine;
4. Arg13Asp; that is, the arginine at position 13 is changed to aspartate.

In one embodiment of the invention a variant of the lantibiotic MU1140 comprises a 25 Phe1Ile or Phe1Gly amino acid substitution; a Trp4Ala amino acid substitution; a Dha5Ala amino acid substitution; an Arg13Asp amino acid substitution; or combinations thereof. An MU1140 variant of the invention can also comprise, e.g., a Trp4insAla in which an alanine is inserted after the fourth tryptophan residue; or a Δ Trp4 in which there is a deletion of the tryptophan at position 4; or both of these 30 changes in the primary amino acid sequence.

Biologically active equivalents of MU1140 lantibiotic polypeptides can have one or more conservative amino acid variations or other minor modifications and retain biological activity. A biologically active equivalent has substantially equivalent

function when compared to the corresponding lantibiotic MU1140. In one embodiment of the invention a lantibiotic mutacin has about 1, 2, 3, 4, or 5 or less conservative amino acid substitutions. A conservative substitution is one in which an amino acid is substituted for another amino acid that has similar properties, such that 5 one skilled in the art of peptide chemistry would expect the secondary structure and general nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, dha, abu, dhb, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, gly, dha, abu, dhb, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. Biologically 10 active equivalent lantibiotic mutacins or other lantibiotic polypeptides can generally be identified by modifying one of the variant lantibiotic mutacin sequences of the invention, and evaluating the properties of the modified lantibiotic mutacin to determine if it is a biological equivalent. A lantibiotic is a biological equivalent if it reacts substantially the same as a lantibiotic mutacin of the invention in an assay 15 such as a zone of inhibition assay, e.g. has 90-110% of the activity of the original lantibiotic mutacin.

Recombinant *S. mutans* strains of the invention comprise a polynucleotide that expresses a functional variant MU1140. Biological activity of a variant MU1140 can be assayed using, e.g., zone of inhibition assays (see Example 2). Recombinant 20 *S. mutans* strains produce enough variant MU1140 to outcompete and substantially eliminate wild-type, cariogenic *S. mutans* from the oral cavity of a host (e.g., reduce the number of wild-type *S. mutans* by about 5, 10, 25, 50, 75, 90, 95, 99, or 100% (or any range between about 5 % and about 100%)).

A lantibiotic of the invention can be covalently or non-covalently linked to an 25 amino acid sequence to which the lantibiotic is not normally associated with in nature, i.e., a heterologous amino acid sequence. A heterologous amino acid sequence can be from a non-*Streptococcus mutans* organism, a synthetic sequence, or an *S. mutans* sequence not usually located at the carboxy or amino terminus of a lantibiotic of the invention. Additionally, a lantibiotic of the invention can be 30 covalently or non-covalently linked to compounds or molecules other than amino acids such as indicator reagents. A lantibiotic of the invention can be covalently or non-covalently linked to an amino acid spacer, an amino acid linker, a signal sequence, a stop transfer sequence, TMR stop transfer sequence, a transmembrane

domain, a protein purification ligand, or a combination thereof. A polypeptide can also be linked to a moiety (i.e., a functional group that can be a polypeptide or other compound) that facilitates purification (e.g., affinity tags such as a six-histidine tag, trpE, glutathione-S-transferase, maltose binding protein, staphylococcal Protein A or 5 com), or a moiety that facilitates polypeptide stability (e.g., polyethylene glycol; amino terminus protecting groups such as acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl or t-butyloxycarbonyl; carboxyl terminus protecting groups such as amide, methylamide, and ethylamide). In one embodiment of the invention a protein purification ligand can be one or more amino acid residues at, for example, 10 the amino terminus or carboxy terminus of a polypeptide of the invention. An amino acid spacer is a sequence of amino acids that are not associated with a polypeptide of the invention in nature. An amino acid spacer can comprise about 1, 5, 10, 20, 100, or 1,000 amino acids.

If desired, a lantibiotic of the invention can be part of a fusion protein, which 15 can contain heterologous amino acid sequences. Heterologous amino acid sequences can be present at the C or N terminus of a lantibiotic of the invention to form a fusion protein. More than one lantibiotic of the invention can be present in a fusion protein. Fragments of lantibiotics of the invention can be present in a fusion protein of the invention. A fusion protein of the invention can comprise one or more 20 lantibiotic of the invention, fragments thereof, or combinations thereof.

In one embodiment of the invention, a recombinant *S. mutans* strain of the invention is ATCC 55676 (deposited under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty)), which has 25 been genetically engineered to express a variant MU1140 as described herein.

Production of a mutant MU1140 lantibiotic with enhanced biological activity as compared to a wild-type MU1140 lantibiotic can therefore provide an *S. mutans* with a selective advantage over non-MU1140-producing *S. mutans* strains present in the oral cavity of a host. The variant MU1140, when expressed by a recombinant *S. 30 mutans* strain of the invention, eliminates the resident, MU1140-susceptible *S. mutans* strains, thus interfering with colonization of MU1140-susceptible strains and promoting recombinant *S. mutans* colonization of the oral cavity. Since the wild-type,

native *S. mutans* is displaced from the oral cavity, the incidence and/or severity of dental caries is reduced.

In one embodiment of the invention the effector strain can additionally express lanB, lanC, lanE, lanF, lanG, lanK, lanM, lanP, lanR, lanT or combinations of two or 5 more of these *S. mutans* polypeptides.

Lactic Acid Expression Deficiency

"Lactic acid deficient" or "deficiency in lactic acid production" means that a recombinant *S. mutans* strain produces substantially decreased amounts of lactic acid relative to wild-type *S. mutans*. Substantially decreased amounts of lactic acid 10 are about 40, 50, 60, 70, 80, 90, 95, or 100% (or any range between about 40% and about 100%) less lactic acid than is produced by a wild-type *S. mutans* strain (e.g. *S. mutans* strain UA159 (ATCC 700610)) or other species belonging to the mutans streptococcus group including *Streptococcus sobrinus* (e.g. *S. sobrinus* strain SL1 (ATCC 33478)), *Streptococcus rattus* (e.g., *S. rattus* strain FA1 (ATCC 19645)), 15 *Streptococcus cricetus* (*S. cricetus* strain HS6 (ATCC 19642)), and *Streptococcus ferus* (*S. ferus* strain 8S1)). In one embodiment of the invention, a lactic acid-deficient *S. mutans* effector strain produces no detectable lactic acid. Lactic acid expression can be detected as described in, e.g., Hillman *et al.*, Infect. Immun. 62:60 (1994); Hillman *et al.*, Infect. Immun. 64:4319 (1996); Hillman *et al.*, 1990, Infect. 20 Immun., 58:1290-1295.

Recombinant *S. mutans* strains of the invention can be lactic acid deficient as a result of a non-functional, inactivated, partially functional, or partially inactivated regulatory region, translational signal, transcriptional signal, or structural sequence in the lactic acid synthesis pathway. Regulatory regions, translational signals, and 25 transcriptional signals include, e.g., promoters, enhancers, ribosome binding sites, CAAT box, CCAAT box, Pribnow box, TATA box, etc. Nonfunctional or inactivated means that the known wild-type function or activity of the polynucleotide, gene, polypeptide or a protein has been eliminated or highly diminished by about 80, 90, 95, or 100% (or any range between about 80% and about 100%) as compared to a 30 wild-type polynucleotide, gene, polypeptide or protein. Partially functional or partially inactivated means that the known wild-type function or activity of the polynucleotide, gene, polypeptide or a protein has been partially diminished by about 20, 30, 40, 50,

60, 70, 79% (or any range between about 20% and about 79%) as compared to a wild-type polynucleotide, gene, polypeptide or protein.

Inactivation or partial inactivation, which renders the polynucleotide, gene, polypeptide, or protein non-functional or partially functional, can be accomplished by 5 methods such as incorporating mutations (e.g., point mutations, frame shift mutations, substitutions, deletions (part of or an entire signal, region or structural polynucleotide), interruptions, and/or insertions) in polynucleotides involved in the lactic acid synthetic pathway. A mutation in a polynucleotide involved in lactic acid synthesis can affect expression of lactic acid such that the expressed amount of 10 lactic acid is diminished by about 20, 30, 40, 50, 60, 70, 80, 90, 95% or more as compared to a wild-type *S. mutans* strain.

For example, inactivation or partial inactivation of lactic acid expression can be effected by inactivating or partially inactivating, e.g., the lactate dehydrogenase (*ldh*) gene by deleting part of or the entire *ldh* structural polynucleotide or part of or 15 the entire *ldh* promoter. Also, inactivation or partial inactivation of lactic acid expression can be effected by inactivating or partially inactivating genes encoding enzymes involved in carbohydrate transport, e.g., the phosphoenolpyruvate phosphotransferase system (*pts*) gene(s), by deleting part of or the entire *pts* structural polynucleotide or part of or the entire *pts* promoter. See e.g., Cvitkovitch 20 *et al.*, J. Bacteriol. 177:5704 (1995). Inactivation or partial inactivation of lactic acid expression can be effected by inactivating or partially inactivating genes encoding enzymes involved in intracellular and extracellular polysaccharide storage, e.g., the glycogen synthase (*glgA*) gene (see e.g., Spatafora *et al.*, Infect. Immun. 63:2556 (1995)) and the fructosyltransferase (*ftf*) gene (see e.g., Schroeder *et al.*, Infect. 25 Immun. 57:3560 (1989)), by deleting part of or the entire *glgA* or *ftf* structural polynucleotide or part of or the entire *glgA* or *ftf* promoter.

One or more defects in the lactic acid synthesis pathway can be introduced by mutagenesis (i.e., exposure of *S. mutans* to a mutagen), selection of spontaneous mutants, or genetic manipulation using recombinant techniques. These techniques 30 are well known in the art (see, e.g., Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). In one embodiment of the invention, the lactic acid synthesis pathway defect is introduced using recombinant techniques, e.g., introduction of a defective

ldh structural gene into the bacterium and subsequent site-specific recombination to replace the wild-type *ldh* with the defective *ldh*. The *S. mutans* *ldh* gene has been cloned, its nucleotide sequence determined (GenBank accession number M72545), and the recombinant *ldh* gene expressed in *Escherichia coli* (Hillman *et al.*, 1990, 5 Infect. Immun., 58:1290-1295; Duncan *et al.*, 1991, Infect. Immun., 59:3930-3934). Hillman *et al.* deleted essentially the entire open reading frame of *ldh* from a *S. mutans* strain (J. Appl. Microbiol. 102:1209 (2007)).

Alcohol Dehydrogenase Production

Because defects in lactic acid synthesis are lethal for *S. mutans*, the defect in 10 the recombinant, lactic acid-deficient *S. mutans* strains must be complemented by the production of a recombinant alcohol dehydrogenase (ADH). See e.g., Hillman *et al.*, Infect. Immun. 64:4319 (1996). Production of the recombinant ADH prevents accumulation of metabolites, e.g., pyruvate, that otherwise causes the death of lactic acid-deficient *S. mutans*.

An *S. mutans* strain can be genetically engineered to express a recombinant alcohol dehydrogenase for example, alcohol dehydrogenase B, alcohol dehydrogenase II, or iron-containing alcohol dehydrogenase from *Zymomonas mobilis* (see e.g., GenBank Accession No. M15394; Conway *et al.*, 1987, J. Bacteriol., 169:2591-2597), alcohol dehydrogenase from *Streptococcus rattus*, iron-containing alcohol dehydrogenase from *Commensalibacter intestini*, iron-containing alcohol dehydrogenase from *Azotobacter vinelandii*, iron-containing alcohol dehydrogenase from *Enterobacteriaceae bacterium*, alcohol dehydrogenase from *Pseudomonas fluorescens*, iron-containing alcohol dehydrogenase from *Dickeya zeae*, alcohol dehydrogenase from *Proteus mirabilis*, iron-containing alcohol dehydrogenase from *Rhodoferax ferrireducens*, iron-containing alcohol dehydrogenase from *Rhodospirillum rubrum*, alcohol dehydrogenase from *Pseudomonas brassicacearum*, alcohol dehydrogenase II from *Pseudomonas syringae*, alcohol dehydrogenase from *Dickeya dadantii*, alcohol dehydrogenase from *Citrobacter rodentium*, iron-containing alcohol dehydrogenase from *Shewanella putrefaciens*, alcohol dehydrogenase from *Vibrio nigripulchritudo*, alcohol dehydrogenase from *Enterobacter aerogenes*, alcohol dehydrogenase from *Pseudomonas savastanoi*, alcohol dehydrogenase from *Salmonella enterica*, iron-containing alcohol dehydrogenase from *Photobacterium leiognathi*, alcohol 20 25 30

dehydrogenase from *Photobacterium damselae*, alcohol dehydrogenase from *Xenorhabdus nematophila*, alcohol dehydrogenase from *Xenorhabdus bovienii*, alcohol dehydrogenase II from *Pseudomonas entomophila*, alcohol dehydrogenase II from *Shewanella vilacea*, alcohol dehydrogenase from *Vibrio sinaloensis*, alcohol 5 dehydrogenase from *Shewanella pealeana*, alcohol dehydrogenase from *Vibrio angustum*, alcohol dehydrogenase from *Edwardsiella tarda*, alcohol dehydrogenase from *Salmonella bongori*, iron-containing alcohol dehydrogenase from *Enterobacter asburiae*, alcohol dehydrogenase from *Escherichia coli*, alcohol dehydrogenase 4 from *Vibrio parahaemolyticus*, alcohol dehydrogenase from *Vibrio splendidus*. In 10 one embodiment of the invention, a polynucleotide encoding a bacterial alcohol dehydrogenase or iron-containing alcohol dehydrogenase has at least about 60, 65, 75, 80, 90, 95, 98, 99, or 100% (or any range between about 65% and 100%) homology to *Zymomonas mobilis* alcohol dehydrogenase B.

Additionally, an ADH-encoding polynucleotide can be derived from *S. mutans*, 15 so that introduction of the ADH-encoding polynucleotide, in combination with the native *S. mutans adh* gene, provides for multiples copies of ADH-encoding polynucleotides in the *S. mutans* genome. Alternatively, the recombinant ADH polynucleotide can be generated by introducing a mutation in the regulatory mechanism of the *S. mutans adh* gene to upregulate the production of ADH (e.g., a 20 mutation in the *adh* promoter to provide increased transcription of the *adh* gene).

An *adh* polynucleotide can be introduced into a *S. mutans* strain of the invention using well-known recombinant techniques, for example, transforming the *S. mutans* strain with polynucleotides encoding an ADH polypeptide. Transforming or transformation means that a *S. mutans* has a non-native nucleic acid sequence 25 integrated into its genome or as a plasmid that is maintained through multiple generations. The *adh* polynucleotide expresses a functional ADH polypeptide such that an *S. mutans* strain of the invention is viable despite the inactivation of lactic acid expression.

Methods for identification, cloning, stable transformation, and expression of 30 polynucleotides encoding, e.g., ADH are routine and well known in the art (see, for example, Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). For example, isolation of polynucleotides encoding ADH can be performed by PCR amplification of

the molecule from genomic DNA or from a preexisting clone of the gene. Expression of recombinant ADH can be accomplished by operably linking the *adh* structural polynucleotide to a promoter that facilitates expression in *S. mutans* (e.g., *spaP* or the native *ldh* promoter).

5 Production of a functional ADH can be assayed by, for example, using conventional ADH activity assays (e.g., assays for NAD-dependent oxidation of ethanol) that are well known in the art (Neal *et al.*, 1986, Eur. J. Biochem., 154:119-124). Hillman *et al.* constructed a strain of *S. mutans* that expressed a functional, recombinant ADH. See e.g., Hillman *et al.*, Infect. Immun. 68:543 (2000).

10 **Auxotrophy**

Recombinant *S. mutans* strains of the invention can optionally be genetically engineered to be auxotrophic for an organic substance not normally present in the oral cavity or diet of a host so that the oral cavity colonization by the recombinant *S. mutans* strains can be controlled. That is, the recombinant *S. mutans* strains can 15 optionally be genetically engineered so that they are unable to synthesize a particular organic compound required for growth. For example, the strains of the invention can be auxotrophs for a D-amino acid, such as a D-alanine. Colonization of the auxotrophic strains can then be controlled by regulating the amount of the organic substance in the oral cavity. For example, colonization can be promoted by 20 providing the organic compound periodically to the oral cavity and colonization can be terminated by withholding administration of the organic substance to the oral cavity.

For example, D-alanine is not normally produced or present in the oral cavity or diet of mammals above trace amounts. Therefore, if a recombinant *S. mutans* of 25 the invention was auxotrophic for D-alanine, then D-alanine would need to be periodically delivered to the oral cavity of the mammal to maintain the colonization of a recombinant *S. mutans* of the invention in the oral cavity. In the absence of delivery of D-alanine to the oral cavity, the recombinant *S. mutans* strains of the invention will eventually die out.

30 In one embodiment of the invention, a recombinant *S. mutans* is alanine racemase deficient. Alanine racemase is required for D-alanine metabolism. "Alanine racemase deficient" or "deficiency in alanine racemase production" means that a recombinant *S. mutans* strain produces substantially decreased amounts of

alanine racemase relative to wild-type *S. mutans*. Substantially decreased amounts of alanine racemase are about 40, 50, 60, 70, 80, 90, 95, or 100% (or any range between about 40% and about 100%) less alanine racemase than is produced by a wild-type *S. mutans* strain. In one embodiment of the invention, an alanine racemase deficient recombinant *S. mutans* strain produces no detectable alanine racemase. Alanine racemase can be assayed as described in, e.g., Wantanabe *et al.*, *J. Biochem.* 126:781 (1999).

Inactivation or partial inactivation, which renders the polynucleotide, gene, polypeptide, or protein non-functional or partially functional, can be accomplished by methods such as incorporating mutations (e.g., point mutations, frame shift mutations, substitutions, deletions (part of or an entire signal, region or structural polynucleotide), interruptions, and/or insertions in genes involved in the alanine racemase synthesis. A mutation in a polynucleotide involved in alanine racemase synthesis can effect expression of alanine racemase such that the expressed amount of alanine racemase is diminished by about 20, 30, 40, 50, 60, 70, 80, 90, 95% or more as compared to a wild-type *S. mutans* strain.

For example, inactivation or partial inactivation of alanine racemase expression can be effected by inactivating or partially inactivating, e.g., the *dal* gene by deleting part or all of the *dal* structural polynucleotide or part or the entire *dal* promoter.

Bacterial auxotrophs can be generated using a variety of techniques well known in the art, such as chemical mutagenesis, selection of spontaneous mutants, and/or recombinant techniques (e.g., transposon mutagenesis, replacement by recombination with a defective or non-functional gene). For example, D-alanine auxotrophic *S. mutans* strains can be generated by introduction of a defect in the gene encoding alanine racemase (*dal*), the enzyme that converts L-alanine to D-alanine. Such strains have been generated. See, e.g., Hillman *et al.*, *J. Appl. Microbiol.* 102: 1209-1219 (2007).

ComE Deficiency

30 Optionally, a recombinant *S. mutans* strain of the invention can comprise an inactivated or non-functional *comE* gene. A strain with an inactivated or non-functional *comE* gene would be less prone to transformation because ComE is

important in the uptake of environmental DNA. Furthermore, *comE* cannot be complemented.

"ComE deficient" or "deficiency in ComE production" means that a recombinant *S. mutans* strain produces substantially decreased amounts of ComE protein relative to wild-type *S. mutans*. Substantially decreased amounts of ComE are about 40, 50, 60, 70, 80, 90, 95, or 100% (or any range between about 40% and about 100%) less ComE protein than is produced by a wild-type *S. mutans* strain. In one embodiment of the invention, a ComE deficient recombinant *S. mutans* strain produces no detectable ComE protein. ComE expression can be assayed as described in, e.g., Chen & Gotschlich, *J. Bact.* 183:3160 (2001).

Recombinant *S. mutans* strains of the invention can be ComE deficient as a result of a non-functional, inactivated, partially functional, or partially inactivated regulatory region, translational signal, transcriptional signal, or structural sequence in ComE synthesis.

Inactivation or partial inactivation, which renders the polynucleotide, gene, polypeptide, or protein non-functional or partially functional includes methods such as incorporating mutations (e.g., point mutations, frame shift mutations, substitutions, deletions (part of or an entire signal, region or structural polynucleotide), interruptions, and/or insertions) in polynucleotides involved in ComE synthesis. A mutation in a polynucleotide involved in ComE synthesis can effect expression of ComE such that the expressed amount of ComE is diminished by about 20, 30, 40, 50, 60, 70, 80, 90, 95% or more as compared to a wild-type *S. mutans* strain.

For example, inactivation or partial inactivation of ComE expression can be effected by inactivating or partially inactivating, e.g., the *comE* gene by deleting part of or the entire *comE* structural gene or part of or the entire *comE* promoter. Other genes involved in DNA uptake such as *comA*, *comB*, *comC*, and *comD*, can also or alternatively be inactivated or partially inactivated.

The defect in ComE synthesis can be introduced by mutagenesis (i.e., exposure of the bacterium to a mutagen), selection of spontaneous mutants, or genetic manipulation using recombinant techniques. A *S. mutans* strain with a mutated *comE* gene has been constructed. See, e.g., Hillman *et al.*, *J. Appl. Microbiol.* 102: 1209-1219 (2007).

Polynucleotides

Polynucleotides of the invention contain less than an entire microbial genome and can be single- or double-stranded nucleic acids. A polynucleotide can be RNA, DNA, cDNA, genomic DNA, chemically synthesized RNA or DNA or combinations thereof. The polynucleotides can be purified free of other components, such as 5 proteins, lipids and other polynucleotides. For example, the polynucleotide can be 50%, 75%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% purified. A nucleic acid molecule existing among hundreds to millions of other nucleic acid molecules within, for example, cDNA or genomic libraries, or gel slices containing a genomic DNA 10 restriction digest are not to be considered an isolated polynucleotide.

The polynucleotides of the invention encode the polypeptides of the invention described above (e.g., MU1140 polypeptides, ADH polypeptides, ComE polypeptides, D-amino acid synthesis polypeptides, and lactic acid synthesis polypeptides). In one embodiment of the invention the polynucleotides encode a 15 variant mutacin 1140 polypeptides shown in SEQ ID NOs:20-27, combinations thereof, or fragments thereof. In one embodiment of the invention the effector strain can additionally express *lanB*, *lanC*, *lanE*, *lanF*, *lanG*, *lanK*, *lanM*, *lanP*, *lanR*, *lanT* or combinations of two or more of these *S. mutans* polynucleotides.

Polynucleotides of the invention can consist of less than about 600, 500, 400, 20 300, 200, 100, 66, 60, 50, 45, 30, 15 (or any range between about 600 and 15) contiguous polynucleotides. The purified polynucleotides can comprise additional heterologous nucleotides and/or additional homologous polynucleotides. Polynucleotides of the invention can comprise other nucleotide sequences, such as sequences coding for linkers, signal sequences, TMR stop transfer sequences, 25 transmembrane domains, or ligands useful in protein purification such as glutathione-S-transferase, histidine tag, and *Staphylococcal* protein A. One embodiment of the invention provides a purified polynucleotide comprising at least about 6, 10, 15, 20, 25, 30, 40, 45, 50, 60, 66, or more contiguous nucleotides of encoding SEQ ID NOs:20-27.

30 Polynucleotides of the invention can be isolated. An isolated polynucleotide is a naturally-occurring polynucleotide that is not immediately contiguous with one or both of the 5' and 3' flanking genomic sequences that it is naturally associated with. An isolated polynucleotide can be, for example, a recombinant DNA molecule of any

length. Isolated polynucleotides also include non-naturally occurring nucleic acid molecules. Polynucleotides of the invention can encode full-length polypeptides, polypeptide fragments, and variant or fusion polypeptides.

Degenerate nucleotide sequences encoding polypeptides of the invention, as well as homologous nucleotide sequences that are at least about 80, or about 90, 5 95, 96, 97, 98, or 99% identical to the polynucleotide sequences of the invention and the complements thereof are also polynucleotides of the invention. Degenerate nucleotide sequences are polynucleotides that encode a polypeptide of the invention or fragments thereof, but differ in nucleic acid sequence from the given 10 polynucleotide sequence due to the degeneracy of the genetic code.

Percent sequence identity has an art recognized meaning and there are a number of methods to measure identity between two polypeptide or polynucleotide sequences. See, e.g., Lesk, Ed., *Computational Molecular Biology*, Oxford University Press, New York, (1988); Smith, Ed., *Biocomputing: Informatics And 15 Genome Projects*, Academic Press, New York, (1993); Griffin & Griffin, Eds., *Computer Analysis Of Sequence Data, Part I*, Humana Press, New Jersey, (1994); von Heinje, *Sequence Analysis In Molecular Biology*, Academic Press, (1987); and Gribskov & Devereux, Eds., *Sequence Analysis Primer*, M Stockton Press, New 20 York, (1991). Methods for aligning polynucleotides or polypeptides are codified in computer programs, including the GCG program package (Devereux *et al.* (1984) *Nuc. Acids Res.* 12:387), BLASTP, BLASTN, FASTA (Atschul *et al.* (1990) *J. Molec. Biol.* 215:403), and Bestfit program (Wisconsin Sequence Analysis Package, Version 25 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) which uses the local homology algorithm of Smith and Waterman ((1981) *Adv. App. Math.*, 2:482-489). For example, the computer program ALIGN which employs the FASTA algorithm can be used, with an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2.

When using any of the sequence alignment programs to determine whether a particular sequence is, for instance, about 95% identical to a reference sequence, 30 the parameters are set such that the percentage of identity is calculated over the full length of the reference polynucleotide and that gaps in identity of up to 5% of the total number of nucleotides in the reference polynucleotide are allowed.

Polynucleotides of the invention can be isolated from nucleic acid sequences present in, for example, a bacterial sample. Polynucleotides can also be synthesized in the laboratory, for example, using an automatic synthesizer. An amplification method such as PCR can be used to amplify polynucleotides from 5 either genomic DNA or cDNA encoding the polypeptides.

Polynucleotides of the invention can comprise coding sequences for naturally occurring polypeptides or can encode altered sequences that do not occur in nature. If desired, polynucleotides can be cloned into an expression vector comprising expression control elements, including for example, origins of replication, promoters, 10 enhancers, or other regulatory elements that drive expression of the polynucleotides of the invention in host cells. An expression vector can be, for example, a plasmid. Minichromosomes such as MC and MC1, bacteriophages, phagemids, yeast artificial chromosomes, bacterial artificial chromosomes, virus particles, virus-like particles, 15 cosmids (plasmids into which phage lambda cos sites have been inserted) and replicons (genetic elements that are capable of replication under their own control in a cell) can also be used.

Methods for preparing polynucleotides operably linked to an expression control sequence and expressing them in a host cell are well-known in the art. See, e.g., U.S. Patent No. 4,366,246. A polynucleotide of the invention is operably linked 20 when it is positioned adjacent to or close to one or more expression control elements, which direct transcription and/or translation of the polynucleotide.

Compositions Comprising Recombinant *S. mutans* of the Invention

Recombinant *S. mutans* strains of the invention can be characterized by: 1) a lactic acid deficiency, and 2) production of a recombinant ADH, 3) variant MU1140 25 production, 4) optionally, an auxotrophy for a specific organic substance (e.g., a D-amino acid such as D-alanine), 5) optionally, a deficiency in ComE expression, or combinations thereof.

Compositions of the invention can comprise one or more strains of recombinant *S. mutans* strains as described herein and a pharmaceutically 30 acceptable or nutritionally acceptable carrier. The carrier is physiologically compatible with the area of the subject to which it is administered. Carriers can be comprised of solid-based, dry materials for formulation into tablet, capsule, lozenge, or powdered form. A carrier can also be comprised of liquid or gel-based materials

for formulations into liquid, gel, and chewing gum forms. The composition of the carrier can be varied so long as it does not interfere significantly with the therapeutic activity of the bacterial strains of the invention. .

A composition can be formulated to be suitable for oral administration in a variety of ways, for example in a solid, semi-solid, liquid (including, e.g., a viscous liquid, a paste, a gel, or a solution), a dried mass, a dentifrice, a mouth wash, an oral rinse, a liquid suspension, a beverage, a topical agent, a powdered food supplement, a paste, a gel, a solid food, an oral rinse, a packaged food, a wafer, lozenge, chewing gum and the like. Other formulations will be readily apparent to one skilled in the art. A composition of the invention can include a nutrient supplement component and can include any of a variety of nutritional agents, as are well known, including vitamins, minerals, essential and non-essential amino acids, carbohydrates, lipids, foodstuffs, dietary supplements, and the like.

Compositions of the invention can also include natural or synthetic flavorings and food-quality coloring agents, all of which are compatible with maintaining viability of the bacterial strains of the invention.

A composition of the invention can include one or more gelling agents that can act as an adhesive agent to adhere the composition to the teeth or mouth. The concentration of the gelling agent may be greater than about 2, 4, 6, 8, 10, 15, 20, 20, 30, 40, 50, 60, 70, 80 or less than about 80, 70, 60, 50, 40, 30, or 20 percent by weight of the composition.

Suitable gelling agents and adhesion agents useful in the present invention include, for example, silicone, polyethylene oxide, polyvinyl alcohol, polyalkyl vinyl ether-maleic acid copolymer (PVM/MA copolymer) such as, Gantrez AN 119, AN 25 139, and S-97, polyvinyl alcohol, polyacrylic acid, Poloxamer 407 (Pluronic), polyvinyl pyrrolidone-vinyl acetate copolymer (PVP/VA copolymer), such as Luviskol VA, and Plasdene S PVP/VA, polyvinyl pyrrolidone (PVP, e.g., K-15 to K-120), Polyquaternium-11 (Gafquat 755N), Polyquaternium-39 (Merquat plus 3330), carbomer or carboxypolymethylene (Carbopol), hydroxypropyl methylcellulose, hydroxyethyl 30 cellulose, hydroxypropyl cellulose, corn starch, carboxymethyl cellulose, gelatin and alginate salt such as sodium alginate, natural gums such as gum karaya, xanthan gum, Guar gum, gum arabic, gum tragacanth, and mixtures thereof.

A humectant or plasticizer can be present in compositions of the invention. Humectants or plasticizers include, for example, glycerin, glycerol, sorbitol, polyethylene glycol, propylene glycol, and other edible polyhydric alcohols. The humectants or plasticizers can be present between at about 1% to about 99%, about 5 10% to about 95%, or at between about 50% and about 80% (or any range between 1% and 99%) by weight of a composition.

Bacteria of the invention can be prepared in, for example, a fermenter. The bacteria can be harvested from the fermenter and can be, for example, concentrated. Bacteria of the invention can be prepared for use by, for example, 10 dehydration, air drying, lyophilizing, freezing, and spray-drying. Bacteria can also be prepared for use by microencapsulation (see e.g., U.S. Pat. No. 6,251,478) or by coating with a protective substance such as, for example, lipid material such as triacylglycerols, waxes, organic esters, soybean oil, cottonseed oil, palm kernel oil, and esters of long-chain fatty acids and alcohols. In one embodiment of the 15 invention the coated or encapsulated bacteria of the invention are released in the oral cavity of the host.

Methods of Treatment and Prevention of Cavities

The recombinant *S. mutans* of the invention can be present in a composition of the invention in a therapeutically effective amount. Therapeutically effective 20 means effective to prevent or reduce the number or incidence (e.g., 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% fewer cavities than controls that did not receive the composition) and/or reduce the severity (e.g., 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% less severe cavities than controls that did not receive the composition) of cavities.

25 A therapeutically effective amount or dosage is an amount or dosage of a composition of the invention at high enough levels to prevent caries and/or reduce caries number and/or caries severity, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical/dental judgment. The therapeutically effective amount or dosage of a composition of the invention may 30 vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the specific form of the source employed, and the particular vehicle from which the composition is applied.

The compositions of the invention can be applied in a therapeutically effective amount to the oral cavity of a host for the treatment and/or prevention of cavities. A composition of the invention may be swallowed or may be rinsed around the oral cavity and then spit out, such that it is not substantially delivered to the 5 gastrointestinal tract. That is, less than about 10, 5, 4, 3, 2, or 1, 0.5, or 0.1% (or any range or value between about 10 and 0.1%) of the delivered bacteria are delivered to the gastrointestinal tract. Treatment means inducing a reduction in the amount or intensity (or combination thereof) of cavities.

Prevention means that substantially no dental caries occur after exposure of 10 the host to one or more recombinant *S. mutans* strains of the invention either permanently (as long as the bacteria of the invention remain in sufficient numbers in the subject's oral cavity), or temporarily (e.g., for about 1, 2, 3, 4, 5, 6 or more months). The bacterial strains of the invention can form at least a part of the transient or indigenous flora of the oral cavity and exhibit beneficial prophylactic 15 and/or therapeutic effects.

Treatment means reducing the amount of wild-type *S. mutans* in the oral cavity of a host such that remineralization of small carious lesions can occur and that further damage to larger carious lesions is stopped or slowed. The amount of wild-type *S. mutans* in the oral cavity can be reduced by about 20, 30, 40, 50, 60, 70, 80, 20 90, or 100% (or any range between about 10 and 100%).

In one embodiment of the invention prevention means prevention in a population of subjects. That is, given a population of subjects, the treatment can prevent dental caries in about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90% or more of the subjects as compared to a control population that did not receive the treatment.

25 In one embodiment of the invention a composition can comprise one or more isolated recombinant strains of the invention along with one or more isolated *Streptococcus oralis* strains and/or one or more isolated *Streptococcus uberis* strains.

30 *Streptococcus oralis* (previously known as *Streptococcus sanguis* Type II) and *S. uberis* are important components in maintaining the normal, healthy balance of microorganisms that compose the periodontal flora. See, Socransky *et al.*, *Oral Microbiol. Immunol.* 3:1-7 (1988); Hillman and Shivers, *Arch. Oral. Biol.*, 33:395-401 (1988); Hillman, *et al.*, *Arch. Oral. Biol.*, 30:791-795 (1985). *S. oralis* produces

hydrogen peroxide, which can inhibit periodontal pathogens such as *Actinobacillus actinomycetemcomitans* (Aa), *Bacteroides forsythus*, and *P. intermedia*. Therefore, *S. oralis* and *S. uberis* can be useful in the maintenance of oral health. Compositions of the invention can comprise one or more isolated strains of *S. oralis*, 5 for example, ATCC 35037, ATCC 55229, ATCC 700233, ATCC 700234 and ATCC 9811. Other strains of *S. oralis* include KJ3 and KJ3sm. KJ3sm is a naturally occurring genetic variant of KJ3 that is resistant to streptomycin. The streptomycin resistance is advantageous because it provides a marker for easy isolation of the bacteria. Additionally, streptomycin resistant strains are slightly attenuated and do 10 not survive as long in an oral cavity as wild-type strains. This property is useful where the goal is to non-persistently colonize the oral cavity of an animal with the bacteria.

S. uberis in plaque has been found to correlate with periodontal health, in particular by interfering with the colonization by periodontal pathogens such as 15 *Porphyromonas gingivalis*, *Campylobacter recta*, and *Eikenella corrodens*. Compositions of the invention can comprise one or more isolated strains of *S. uberis*, for example, ATCC 13386, ATCC 13387, ATCC 19435, ATCC 27958, ATCC 35648, ATCC 700407, ATCC 9927, strain KJ2 or strain KJ2sm. KJ2sm is a naturally occurring genetic variant of KJ2. That is streptomycin resistant and provides the 20 same advantages as for streptomycin-resistant strains of *S. oralis*. One or more isolated strains of *S. oralis* or one or more isolated strains of *S. uberis*, or both, can be used in compositions and methods of the invention. Additional oral care benefits of these compositions of the invention include, for example, the treatment and/or prevention of periodontitis, oral bacterial infections and diseases, oral wounds, 25 *Candida* or fungal overgrowth, halitosis, or xerostomia-induced dental caries and associated periodontal diseases, the promotion of wound healing, teeth whitening or a combination thereof to a subject.

One embodiment of the invention provides a method for treating dental caries comprising administering a composition comprising one or more recombinant *S. mutans* strains of the invention to the oral cavity of a subject in need thereof. That is, 30 the subject has one or more dental caries.

One embodiment of the invention provides for the prevention of dental caries in normal, healthy subjects. Another embodiment of the invention provides for

treatment and/or prevention of dental caries in subjects having an increased susceptibility to dental caries as compared to normal, healthy subjects. In both embodiments, the method consists of administering a composition comprising one or more recombinant *S. mutans* strains to the oral cavity of a subject.

5 Subjects have an increased susceptibility to dental caries when they are more likely than a normal, healthy host to develop dental caries. Such hosts may have, for example, decreased saliva production (e.g., patients undergoing radiation therapy on the head or neck, patients having Sjögren's syndrome, diabetes mellitus, gastro-esophageal reflux disease, diabetes insipidus, or sarcoidosis, patients taking 10 antihistamines and antidepressants or other medications that cause "dry mouth"), smokers, smokeless tobacco users, patients having a genetic predisposition (Shuler, J. Dent. Ed. 65:1038 (2001)), or are infants (0 to 2 years old or 6 months to 2 years old), children (3 years to 18 years old), or elderly (older than 65).

15 The invention also provides a method of reducing the amount in a subject of bacteria that can cause dental caries. The method comprises administering a composition comprising one or more recombinant *S. mutans* strains of the invention to the oral cavity of a subject having one or more strains or species of bacteria that can cause dental caries. The compositions can be administered just once or on a regular basis. The number of the one or more strains or species of bacteria that can 20 cause dental caries in the subject is reduced. The reduction can be about a 5, 10, 25, 50, 75, 90, 95, 99, or 100% (or any range between about 5% and about 100%) reduction in numbers.

25 Optionally, prior to the administration of the composition of the invention, one or more bacteria that can cause dental caries can be detected and/or quantitated using any detection/quantitation method known in the art. Those of skill in the art are aware of methods of detection of bacteria that cause dental caries. Optionally, prior to the administration of the composition of the invention, one or more dental caries can be diagnosed in the subject using any methodology known in the art.

Another embodiment of the invention provides a method of preventing dental 30 caries in a subject. The method comprises obtaining data regarding a therapeutically effective dosage range for prevention of dental caries in a particular type of subject and determining the effective dosage range of recombinant *S. mutans* for the particular type of subject. A particular type of subject can be, for

example, a subject with decreased saliva production (e.g., patients undergoing radiation therapy on the head or neck, patients having Sjögren's syndrome, diabetes mellitus, gastro-esophageal reflux disease, diabetes insipidus, or sarcoidosis, patients taking antihistamines and antidepressants or other medications that cause 5 "dry mouth"), smokers, smokeless tobacco users, patients having a genetic predisposition, or are infants (0 to 2 years old or 6 months to 2 years old), children (3 years to 18 years old), or elderly (older than 65). The determined therapeutically effective dosage range for the particular type of subject of one or more recombinant *S. mutans* strains of the invention are administered to the oral cavity of the particular 10 type of subject.

Compositions can be administered to the oral cavity of a host or subject such as an animal, including a mammal, for example, a human, a non-human primate, a dog, a cat, a horse, a bovine, a goat, or a rabbit.

The compositions of the invention can be orally administered in for example, 15 food, water, a dentifrice, a gel, a paste, an emulsion, aerosol spray, chewing gum, lozenge, tablet, capsule, or a liquid suspension. The bacteria can either be already formulated into food, water, gel or other carrier or can be a composition (e.g., powder, tablet or capsule) that is added to the carrier (e.g., food, water, dentifrice, gel, paste, emulsion, aerosol spray, or liquid suspension) by the user prior to 20 consumption.

One embodiment of the invention provides a method of non-persistently colonizing an oral cavity of a subject with therapeutically-effective bacteria comprising administering to the oral cavity of a subject a composition of the invention. In one embodiment of the invention the administered bacterial strains do 25 not permanently colonize the oral cavity, rather the strains are present in the oral cavity for about 1 day, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 3 months or about 12 months after administration of the bacteria.

In another embodiment of the invention, recombinant strains of *S. mutans* persistently colonize an oral cavity of a host for a long term period, e.g., 2 weeks, 1 30 month, 3 months, 6 months, 1 year, 5 years, or more or for the life of the host.

Compositions of the invention can be administered at a dose of about 1×10^3 , 1×10^5 , 1×10^7 , 1×10^8 , 1×10^9 , or 1×10^{11} CFU (or any range or value between about 1×10^3 and about 1×10^{11}) of viable bacteria. A dose of a composition of the invention

can be administered at four times a day, three times a day, twice a day, once a day, every other day, two times a week, weekly, biweekly, monthly, or yearly. One, two, or more doses of a composition of the invention can be administered per day for about 1 day, about 1 week, about 2 weeks, about 1 month, about 2 months, about 3 months, about a year or more. In one embodiment of the invention, a composition of the invention is administered one time and is effective for a long term period.

A composition of the invention can comprise bacterial strains at a concentration between about 0.01% and about 50%, or about 0.1% to about 25%, or about 1.0% to about 10% or any ranges or values in between 0.01% and 50% by weight of the composition.

A kit of the invention can contain a single dose, a one week, one month, two month, three month, four month, five month, six month, or 12 month supply of a composition of the invention. A composition of the invention can be packaged and, in turn, a plurality of the packaged compositions can be provided in a storage container or outer package or carton. Where the one or more strains of *S. mutans* are auxotrophic, the kit can include a bacterial auxotroph-maintaining amount of an organic substance, e.g., a composition comprising a D-amino acid such as D-alanine.

Where a composition of the invention comprises one or more strains of *S. mutans* that are auxotrophic for an organic substance, a bacterial auxotroph-maintaining amount of an organic substance can be administered to hosts to maintain the recombinant *S. mutans* in the oral cavity. A "bacterial auxotroph-maintaining amount" is an amount of an organic substance sufficient to maintain viability of the recombinant *S. mutans* auxotroph in the oral cavity. For example, where the recombinant *S. mutans* is auxotrophic for D-alanine, a D-alanine bacterial auxotroph-maintaining amount is an amount of D-alanine sufficient for survival of the D-alanine auxotrophic strain in the host's oral cavity. In general, a single dose of a D-alanine bacterial auxotroph-maintaining amount of D-alanine contains about 1, 5, 10, 20, 25, 50, 75 or 100 mg (or any range between about 1 and about 100 mg). The concentration of D-alanine in a composition in the form of a solution is about 0.01, 1, 10, 25, 50, 75, 100, or 167 mg/ml (the latter being a saturated solution of D-alanine in water at 25°C) (or any range between about 0.01 and about 167 mg/ml). The

concentrations of D-alanine in a composition can vary according to the carrier used and the saturation point of D-alanine in that specific carrier.

The organic substance, e.g., D-alanine, required for maintenance of the auxotrophic, recombinant *S. mutans* in the oral cavity can be formulated as a 5 mouthwash, chewing gum, dental floss, toothpaste, chewable tablet, food, beverage or any other formulation suitable for oral administration to the host's oral cavity. In addition to the organic substance (e.g., D-alanine), the composition can additionally contain flavoring agents, coloring agents, fragrances, or other compounds that increase the palatability of the composition and/or enhance patient compliance 10 without compromising the effectiveness of the organic substance contained in the composition.

All patents, patent applications, and other scientific or technical writings referred to anywhere herein are incorporated by reference herein in their entirety. The invention illustratively described herein suitably can be practiced in the absence 15 of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of", and "consisting of" may be replaced with either of the other two terms, while retaining their ordinary meanings. The terms and expressions which have been employed are used as terms of description and not of limitation, 20 and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by embodiments, optional features, modification and variation 25 of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

In addition, where features or aspects of the invention are described in terms of 30 Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

The following are provided for exemplification purposes only and are not intended to limit the scope of the invention described in broad terms above.

EXAMPLES

Example 1: Mutagenesis of MU1140

The *Streptococcus mutans* genome database and *lan* gene cluster, GenBank/EMBL accession number (AF051560), was used to design primers for the 5 mutagenesis and sequencing work. The open reading frame (ORF) of the native MU1140 structural gene (*lanA*) plus 500 base pairs (bp) of 5' and 3' flanking DNA was cloned into the pVA891 plasmid to create p190. The cloned insert in p190 was derived by PCR amplification of chromosomal DNA of *S. mutans* strain JH1140 (ATCC 55676) using the primer sequences of SRWlanA_1 and SRWlanA_2 (see 10 Figure 3). Reagents and media were purchased from Fisher Scientific, and enzymes were purchased from New England BioLabs (Ipswich, MA).

Polymerase Chain Reaction (PCR)

Mutations (see Figure 1B) were introduced into the propeptide region of *lanA*, the structural gene for MU1140, to create the variants of MU1140. See Figure 2. 15 The p190 plasmid (J.D. Hillman, unpublished) was used as a template and the site specific mutations were introduced using two-step PCR. In the first step, the upstream and downstream outside primers (SRWlanA_1 and SRWlanA_2) were paired with appropriate inside primers (e.g., SRWlanA_1/Trp4Ala_2 and SRWlanA_2/Trp4Ala_1) (Figure 3), one of which was synthesized to contain an 20 altered base sequence relative to the wild type sequence. The result of this step was the production of two fragments, one that included 5' flanking DNA and a portion of *lanA*, including the site directed base alterations. The second fragment contained the remainder of *lanA* plus 3' flanking DNA. Primers used to produce the MU1140 variants are found in Figure 3. The two fragments were then mixed in equal amounts 25 and subjected to a second round of PCR using the two outside primers, SRWlanA_1 and SRWlanA_2, to yield the final amplicon.

PCR reactions were performed using Taq polymerase in a final volume of 50 μ L containing 0.4 μ mol of each primer, 50 ng of template DNA, 0.016 mM dNTP, and 1 unit of DNA polymerase in 1X polymerase buffer. Amplification conditions for each 30 fragment were as follows: preheat at 95°C for 1 min, followed by 27 cycles incubation with denaturation (95°C) for 30 sec, annealing (56°C) for 30 sec and extension (72°C) for 2 min followed by a final extension (72°C) for 10 min. Both fragments were combined 50:50 and amplified using the two outside primers

SRWlanA_1 and SRWlanA_2 under the same amplification conditions as mentioned above.

The final PCR product was ligated into a TOPO-TA vector (Invitrogen, Carlsbad, CA) following kit directions and transformed into DH5 α -T1[®] cells (Invitrogen) using standard methods and spread on LB plates containing 50 μ g/mL of ampicillin and 40 μ L of X-gal (40mg/mL). Blue-white screening was utilized to identify colonies containing an insert. Plasmid DNA from each colony was purified using a PureYield Plasmid Miniprep System (Promega, Madison, WI) according to the manufacturer's instructions. Purified plasmid was subjected to restriction digest using 5 *EcoRI* and examined by agarose gel electrophoresis to identify those that have a cloned insert of proper size (~1100 bp). Plasmids containing the proper sized insert were sequenced using M13 Forward (-20) primer, 5'-GTAAAACGACGGCCAG-3' (SEQ ID NO:28), to confirm the proper insertion, deletion, or replacement of nucleotide bases.

15 **Recombination**

Restriction enzyme digestion was performed on purified plasmid from colonies harboring a confirmed mutation. The insert were separated from the TOPO plasmid by electrophoresis, excised from the gel, and purified using a Qiagen Gel Extraction Kit (Qiagen, Valencia, CA). The purified insert was then ligated into the *S. mutans* 20 suicide vector, pVA891, in a 3:1 insert:vector ratio using T4 DNA ligase at 16°C overnight. The resultant plasmid was then transformed into DH5 α cells using standard methods and spread on LB plates containing 300 μ g/mL of erythromycin. Colonies which arose following incubation were analyzed to verify proper insert size and sequence as described above.

25 Purified pVA891 DNA containing confirmed inserts was transformed into *S. mutans* strain JH1140 (ATCC 55676) as follows: *S. mutans* was grown overnight then diluted 1:15 in fresh THyex broth (30 g/L THB, 3 g/L yeast extract), 200 μ L of diluted cells were added to a 96 well plate and incubated at 37°C for 2 hours. Two microliters of competence stimulating peptide (CSP, 0.1 μ g/mL; see e.g., Li *et al.*, J. 30 Bacteriol. 183:897 (2001)) was added, and plates were incubated for an additional 6 hours. See Li *et al.*, (2002) J. Bacteriol. 184:2699. Fifty microliters of cells were then plated onto pre-warmed THyex agar plates (30 g/L THB, 3g/L yeast extract, and 15g/L of nutrient agar) containing 300 μ g/mL of erythromycin and incubated at 37°C

for 48 hours. Genomic DNA was extracted from clones that arose utilizing a standard chloroform/phenol extraction method and the DNA was used as template for PCR that used SRWlanA_1 and SRWlanA_2 to identify heterodiploid clones presumed to have one wild type and one mutated copy of the *lanA* gene separated by vector 5 DNA, as previously described by Hillman *et al.*, (2000) *Infect. Immun.* 68:543-549.

Confirming Genetic Identity of Mutant Constructs

Clones containing the desired *lanA* mutations were obtained by spontaneous resolution of the heterodiploid state as follows: several confirmed heterodiploids were grown overnight in 20 mL THyex broth that did not contain erythromycin. The 10 cultures were subcultured (1:20 dilution into fresh media) and again grown overnight to saturation. The cultures were then diluted 100,000 fold and spread onto large THyex agar plates and incubated at 37°C for 48 hours. Resultant colonies were replica patched onto medium with and without erythromycin to identify spontaneous recombinants in which elimination of the pVA891 plasmid (expressing the 15 erythromycin resistance gene) and either the wild-type or mutated *lanA* gene had occurred. Erythromycin sensitive colonies that were identified from the replica plating technique were re-tested on medium with and without erythromycin. The *lanA* region of erythromycin sensitive clones was amplified by PCR as described above. The amplicons generated were sequenced to identify clones possessing only the 20 modified *lanA* genes. BLAST sequence analysis was used to compare the wild-type sequence of *lanA* to the *lanA* of suspected mutants (Figure 2). The mutants generated were: Trp4Ala, Trp4insAla, ΔTrp4, Dha5Ala, Ala_s7insAla, and Arg13Asp.

Example 2: Bioactivity of Mutants

The parent *S. mutans* strain, JH1140 (ATCC 55676), and the mutants were 25 grown to an OD₆₀₀ of 0.8 and diluted to an OD₆₀₀ of 0.2. Samples (2 µL) of the cultures were spotted in triplicate on a pre-warmed THyex agar plate (150 X 15mm) and allowed to air dry. This assay was performed in this manner to help ensure that each sample had the same colony size for comparing zones of inhibition. The plate was incubated for 24 hours at 37°C, and then placed in an oven at 55°C for thirty 30 minutes to kill the bacteria before the *M. luteus* ATCC 272 indicator strain was overlayed in molten top agar. Heat killing the bacteria prevented any further antimicrobial compound production. *M. luteus* ATCC 272 was grown to an OD_{600nm} between 0.4 and 0.8 and diluted to an OD_{600nm} of 0.2. Then, 400 µL of these cells

was added to 10 ml of molten top agar (42°C) (30g/L Todd Hewitt Broth and 7.5g/L Nutrient agar). All 10 mL of top agar containing the standardized suspension was added to each plate containing approximately 50 mL of THyex agar. The plates were allowed to solidify before being inverted and incubated overnight at 37°C. Each 5 inhibitory zone radius was measured in mm from one edge of the colony to the farthest portion of the zone. The area of the inhibitory zone was calculated for each zone and compared to the average zone area of the wild-type (n=10).

Figure 4 illustrates the bioactivity of strains producing variants of MU1140 compared to wild-type MU1140. The results are summarized in Figure 5, which 10 shows that the strains producing Trp4insAla and ΔTrp4 had zones that were not significantly different (Student's *t* test, *p*>.05) than the wild-type. The strain producing Arg13Asp had the largest inhibitory zone area amounting to a 2.57-fold increase relative to wild-type (*p*<.001). The strains producing Trp4Ala and Dha5Ala produced significant (*p*<.001) 2.12-fold and 1.87-fold increases, respectively, relative 15 to the wild-type. The strain producing Ala₈7insAla had the smallest zone area, which amounted to a significant (*p*<.001) 2-fold reduction in zone area when compared to the wild-type. Figure 6 shows the biological activity of strains producing other variants of MU1140 (Phe1Ile and Phe1Gly) compared to wild-type MU1140. The strains producing Phe1Ile and Phe1Gly demonstrated significant (*p*<.001) 1.82-fold 20 and 1.57-fold increases, respectively, relative to the wild-type.

There has been a number of studies that used site directed mutagenesis of the structural gene for nisin and certain other lantibiotics (reviewed by Chatterjee *et al.* (2005) *Chem. Rev.* 105:633) to analyze the importance of particular amino acids in the activity of these molecules. Rarely have these mutations resulted in increased 25 bioactivity.

The most interesting result was obtained for the Arg13Asp mutant. This mutation resulted in an unexpected, highly significant increase in bioactivity when compared to the wild-type. Here there was replacement of a positively charged residue with a negatively charged residue in the hinge region. This finding is contrary 30 to the conventional belief that negative charges for lantibiotics should reduce bioactivity since positive charges are thought to aid in the interaction of the antibiotic with negatively charged lipids present in the target cell membrane. This mutation also removed a trypsin cleavable site from the compound, thereby making it more

stable to enzymatic hydrolysis. Furthermore, the Trp4Ala, Dha5Ala, and Arg13Asp are transversion mutations that would likely not naturally occur.

The mutations to MU1140 described herein are therefore unexpected and unpredictable in view of the prior art and result in variant MU1140 molecules that 5 have vastly improved biological and structural characteristics as compared to wild-type MU1140. Mutations that increase activity are important from the standpoint of improving the colonization potential of an *S. mutans* effector strain. The ability of *S. mutans* strains to colonize the oral cavity of rodents and humans has been previously shown to correlate with the amount and/or activity of MU1140 produced. 10 In addition, the ability of *S. mutans* strains to aggressively displace indigenous strains of *S. mutans* in the oral cavity of rodents and humans has been previously shown to correlate with the amount and/or activity of MU1140 produced. See e.g., Hillman *et al.*, Infect. Immun. 44:141 (1984); Hillman *et al.*, J. Dent. Res. 66:1092 (1987). Therefore, an *S. mutans* effector strain of the invention that expresses a 15 variant MU1140 as described herein will have unexpected and improved characteristics as compared to effector *S. mutans* strains that do not express a variant MU1140 of the invention. That is, *S. mutans* effector strains expressing a variant MU1140 will have improved ability to colonize and aggressively outcompete and replace native *S. mutans* in the oral cavities of the hosts relative to *S. mutans* 20 effector strains that do not express a variant MU1140 as described herein.

Example 3 Minimum Inhibitory Concentration

Wild-type mutacin 1140, mutacin 1140 with a F1I mutation, mutacin 1140 with a W4A mutation, and mutacin 1140 with a R13D mutation was purified to about 90% purity (measured via HPLC). The minimum inhibitory concentration (MIC) of 25 MU1140 and variants of MU1140 was determined against several bacteria. The MIC is the lowest concentration of MU1140 that will inhibit the visible growth of a microorganism after 24 hour incubation. A lower MIC is an indication of greater inhibitory activity. Preparation of the antimicrobial agent and bacterial inoculum for minimum inhibitory concentrations (MICs) was performed by following the method 30 described in Clinical Laboratory Standard Institute (CLSI) M07-8A with some minor modifications. *Streptococcus mutans* UA159 was tested overnight in a shaking incubator to maintain uniform dispersion of the bacteria. *Clostridium difficile* UK1

was tested in an anaerobic chamber at 37°C. The medium used was THyex. The results are shown in Table 1.

Table 1

MU1140 Variant	<i>Streptococcus mutans</i> UA159	<i>Streptococcus pneumonia</i> FA1	<i>Staphylococcus aureus</i> FA1	<i>Micrococcus luteus</i> ATCC10240	<i>Clostridium difficile</i> UK1
Mu1140 Wild-type	2	0.5	16	0.0625	16
Mu1140 F1I	2	0.25	8	0.0156	8
Mu1140W4A	2	0.125	16	0.0312	8
Mu1140R13D	2	4	>16	0.125	16


5 While the MIC is not necessarily lower for each organism for each mutant, each mutant may still have advantages over the wild-type MU1140 because it may, for example, be easier to produce, easier to transport, have better shelf stability, have better serum stability, or have better proteolytic stability, among other advantageous properties.

10

Claims

What is claimed is:

5 1. An isolated recombinant *Streptococcus mutans* strain comprising:
 (a) a mutation in a polynucleotide involved in lactic acid synthesis such that
 expression of lactic acid is diminished by about 80% or more as compared to a wild-
 type *S. mutans* strain;
 10 (b) a recombinant alcohol dehydrogenase polynucleotide;
 (c) a recombinant polynucleotide encoding a lantibiotic comprising Formula I:



15 (SEQ ID NO:1), wherein the following mutations are present: a Phe1Ile mutation or a
 Phe1Gly mutation; a Trp4Ala mutation; a Dha5Ala mutation; an Arg13Asp mutation;
 or combinations of two or more of these mutations.

20 2. The isolated recombinant *Streptococcus mutans* strain of claim 1, wherein the
 mutacin comprising Formula I further comprises a Trp4insAla mutation or a
 ΔTrp4 mutation.

25 3. The isolated recombinant *Streptococcus mutans* strain of claim 1, wherein the
 following amino acid substitutions are present: Abu8Ala, or Dhb14Ala, or both
 Abu8Ala and Dhb14Ala in the lantibiotic comprising Formula I.

30 4. The isolated recombinant *Streptococcus mutans* strain of claim 1, further
 comprising a mutation in a polynucleotide involved in ComE, ComC or both
 ComE and Com C synthesis such that expression of ComE, ComC, or both
 ComE and ComC is diminished by about 80% or more as compared to a wild-
 type *S. mutans* strain.

5. The isolated recombinant *Streptococcus mutans* strain of claim 1, further
 comprising a mutation in a polynucleotide involved in D-amino acid synthesis
 such that expression of the D-amino acid is diminished by about 80% or more
 as compared to a wild-type *Streptococcus mutans* strain.

6. The isolated recombinant *Streptococcus mutans* strain of claim 5, wherein the polynucleotide is *dal* or a promoter for *dal*.
7. The isolated recombinant *Streptococcus mutans* strain of claim 1, wherein the recombinant alcohol dehydrogenase polynucleotide is a *Zymomonas mobilis* alcohol dehydrogenase polynucleotide or a *Streptococcus mutans* alcohol dehydrogenase polynucleotide.
8. A method of reducing the incidence or severity of dental caries in a dental caries-susceptible host comprising administering orally to the host the isolated recombinant *Streptococcus mutans* strain of claim 1 in an amount effective for replacement of dental caries-causing *Streptococcus mutans* host strains in the oral cavity of the host.
9. The method of claim 8, wherein the isolated recombinant *Streptococcus mutans* strain is contained in a mouthwash, toothpaste, chewing gum, floss, chewable tablet, food, or beverage.
10. A pharmaceutical composition for reducing the incidence or severity of dental caries comprising the isolated recombinant *Streptococcus mutans* strain of claim 1 and a pharmaceutically acceptable carrier.





Figure 1B
Schematic of Variations to MU1140

Figure 1A
Wild-type (native) MU1140



Alignment of mutants to Wild-type Sequence

Wild-type	TTCAAAAGTTGG---AGCCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Phe1Gly	GGCAAAAGTTGG---AGCCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Phe1Ile	ATCAAAAGTTGG---AGCCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Trp4Ala	TTCAAAAGTGCA---AGCCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Trp4insAla	TTCAAAAGTTGGCAAGCCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
ΔTrp4	TTCAAAAGT---AGCCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Ser5Ala	TTCAAAAGTTGG---GCACCTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Cys7insAla	TTCAAAAGTTGG---AGCCTTGTGCAACGCCCTGGTTGTGCAAGGACAGGTAGTTCAATAGTTACTGTTGC
Arg13Asp	TTCAAAAGTTGG---AGCCTTGT---ACGCCTGGTTGTGCAGACACAGGTAGTTCAATAGTTACTGTTGC
Wild-type	SEQ ID NO:19
Phe1Gly	SEQ ID NO:20
Phe1Ile	SEQ ID NO:21
Trp4Ala	SEQ ID NO:22
Trp4insAla	SEQ ID NO:23
ΔTrp4	SEQ ID NO:24
Ser5Ala	SEQ ID NO:25
Cys7insAla	SEQ ID NO:26
Arg13Asp	SEQ ID NO:27

Figure 2

Figure 3: Primers Used for Mutagenesis of MU1140

Oligonucleotide	Sequence (5' – 3')
SRWlanA_1	AGAATT CAGGATGCTATCGCTGCTTTTTGTG (SEQ ID NO:1)
SRWlanA_2	AGAATT CAGGAAAGTGCATATGGTTTG (SEQ ID NO:2)
Phe1Gly_1	GATCCAGATACTCGT GG CAAAGTGGAGCCTTGTACG (SEQ ID NO:15)
Phe1Gly_2	CAACTTTGCCACGAGTATCTGGATCGTCGTTGC (SEQ ID NO:16)
Phe1Ile_1	GATCCAGATACTCGT AT CAAAGTGGAGCCTTGTACG (SEQ ID NO:17)
Phe1Ile_2	CAACTTTGATCGAGTATCTGGATCGTCGTTGC (SEQ ID NO:18)
Trp4Ala_1	GCAAGC TTTGACGCCGGTTG (SEQ ID NO:3)
Trp4Ala_2	ACAAAGGCTTG CA CTTTGAAACG (SEQ ID NO:4)
Trp4insAla_1	GCAAGC TTTGACGCCGGTTG (SEQ ID NO:5)
Trp4insAla_2	CAAAGGCTTG CC AACTTTGAAACG (SEQ ID NO:6)
ΔTrp4_1	---AGC CTT GACGCCGGTTG (SEQ ID NO:7)
ΔTrp4_2	CGTACAAAGG CT ACTTTGAAACG (SEQ ID NO:8)
Dha5Ala_1	GCA CTTGACGCCGGTTGTGC (SEQ ID NO:9)
Dha5Ala_2	GGCGTACAAAGTGC CC AACTTTGAA (SEQ ID NO:10)
Alas7InsAla_1	GCAACG CCTGGTTGTGCAAGGAC (SEQ ID NO:11)
Alas7InsAla_2	ACCAGGC GT GCACAAAGGCTCC (SEQ ID NO:12)
Arg13Asp_1	GACACAGG TAGTTCAATAGTTAC (SEQ ID NO:13)
Arg13Asp_2	GAAACTAC CTGT GTCTGCACAACCAG (SEQ ID NO:14)
Outside primers are SRWlanA_1 and SRWlanA_2 and are homologous to the 5' and 3' flanking DNA.	
Underlined section represents the engineered EcoRI site. Mutations are either bolded or dashes.	
Numbering designates forward (1) and reverse (2) for primers.	

Figure 4A**Figure 4B****Figure 4A-B: Zone of Inhibition Plate Assays**

Bioactivity of Strains Producing Variants of MU1140 Compared to Wild-Type MU1140

Variant Produced	Mean Area* (mm ²)	Standard Error of the Mean (SEM)	Ratio of Variant to Wild-Type Activities	Statistical Significance (p value) [#]
MU1140 (wild-type)	204.44	8.90	-	-
Phe1Gly	321.85	46.52	1.57	<.001
Phe1Ile	372.78	75.90	1.82	<.001
Trp4Ala	434.80	46.10	2.12	<.001
Trp4insAla	212.37	24.70	1.04	>.05
ΔTrp4	217.56	35.37	1.06	>.05
Dha5Ala	382.25	31.40	1.87	<.001
Ala ₈ 7insAla	109.41	9.74	0.54	<.001
Arg13Asp	526.06	55.09	2.57	<.001

* Based on 10 independent samples.

[#] Student's t Test

Figure 5




Figure 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/027340

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07K 14/315 (2013.01)

USPC - 424/49

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 38/00, 38/12, 38/16; A61P 31/04; A61Q 11/00; C07C 323/59; C07K 1/02, 1/06, 1/107, 5/12, 14/00, 14/195, 14/315 (2013.01)
USPC - 424/49, 50, 94.4; 435/183, 220, 252.3, 252.35, 253.4; 514/2.3, 2.4, 2.6, 12.2, 21.4; 530/324, 326, 350; 536/23.1, 23.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

CPC - A61K 8/64; A61Q 11/00, 17/005; C07K 1/02, 1/04, 1/062, 1/063, 1/107, 1/1075, 14/32, 14/315 (2013.01)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Patbase, Google Patent, PubMed

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2009/0215985 A1 (KIRICHENKO et al) 27 August 2009 (27.08.2009) entire document	1-10
A	WO 1998/56411 A1 (HILLMAN) 09 June 1998 (09.06.1998) entire document	1-10
A	WO 2008/151434 A1 (HANCOCK et al) 18 December 2008 (18.12.2008) entire document	1-10

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 May 2013

Date of mailing of the international search report

31 MAY 2013

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Faxsimile No. 571-273-3201

Authorized officer:

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774